Prostate cancer trials recruiting in Pennsylvania

All Prostate cancer trials nationally

Cities in Pennsylvania

Recruiting trials in Pennsylvania

• A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  NCT06925737 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
  NCT06863272 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Pittsburgh
• A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
  NCT04729114 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Bala-Cynwyd
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
  NCT06778863 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia
• A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
  NCT06095089 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• A Study of LY4257496 in Participants With Cancer (OMNIRAY)
  NCT07114601 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Pittsburgh
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
  NCT06952803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Hershey, Lancaster, Pittsburgh
• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
  NCT06136650 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Bala-Cynwyd, Philadelphia
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
  NCT06395519 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia
• A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
  NCT05818683 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT07225946 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Allentown, Bala-Cynwyd, Hershey, Pittsburgh
• A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
  NCT07164443 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Bala-Cynwyd, Lancaster, Philadelphia, Pittsburgh
• A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT06533644 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia, Pittsburgh
• A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
  NCT06844383 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• A Study of Tarlatamab for People With Prostate Cancer
  NCT07111507 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
  NCT06457919 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
  NCT04104776 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
  NCT07213674 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Pittsburgh
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06764485 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Allentown, Philadelphia, Willow Grove
• A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
  NCT05125016 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
  NCT03972657 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia
• AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
  NCT07611110 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Pittsburgh
• Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
  NCT05422911 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
  NCT07219303 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
  NCT06235697 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Erie, Jefferson Hills, Monroeville, Pittsburgh
• Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
  NCT05629494 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: Male · Pennsylvania: Hershey
• Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
  NCT04038502 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• Circulating Tumor DNA in High Risk Localized Prostate Cancer
  NCT07222436 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · Pennsylvania: Pittsburgh
• Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
  NCT07234968 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female) · Pennsylvania: Philadelphia
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Pennsylvania: Allentown, Bethlehem, Danville, East Stroudsburg
• Customized TULSA-PRO Ablation Registry
  NCT05001477 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · Pennsylvania: York
• DESTINY-PANTUMOUR04
  NCT07124000 · Phase: Not specified · Ages: 18 Years to 130 Years · Sex: All (male and female) · Pennsylvania: Philadelphia
• Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
  NCT05804318 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• Distance-Based Exercise to Preserve Function and Prevent Disability
  NCT07059884 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Butler, Indiana, New Castle, Pittsburgh
• Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
  NCT06592924 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Chadds Ford, Danville, Dickson City, Hazleton
• Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
  NCT04373564 · Phase: Phase 4 · Ages: 18 Years to 64 Years · Sex: All (male and female) · Pennsylvania: Hershey, Philadelphia
• Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
  NCT06613100 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network
  NCT05627219 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• FOG-001 in Locally Advanced or Metastatic Solid Tumors
  NCT05919264 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia, Pittsburgh
• FTT PET/CT in Metastatic Prostate Cancer
  NCT05242744 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
  NCT07332455 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer
  NCT06517901 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Pennsylvania: Hershey
• Hypofractionated WPPT With HDR Boost
  NCT06591819 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia
• International Registry for Men With Advanced Prostate Cancer (IRONMAN)
  NCT03151629 · Phase: Not specified · Ages: 21 Years and older · Sex: Male · Pennsylvania: Doylestown, Philadelphia, West Reading
• Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
  NCT05803941 · Phase: Phase 4 · Ages: 18 Years to 100 Years · Sex: Male · Pennsylvania: Pittsburgh
• Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
  NCT06134232 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Bala-Cynwyd, Lancaster
• Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
  NCT06780670 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · Pennsylvania: Philadelphia
• PSMA PET Combined With MRI for the Detection of PCa
  NCT07052214 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
  NCT06138067 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Chambersburg
• Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
  NCT05487846 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
  NCT04472338 · Phase: Not specified · Ages: 40 Years and older · Sex: Male · Pennsylvania: Philadelphia
• Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
  NCT04175431 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Pittsburgh
• Prostate Tissue BioBank
  NCT06659614 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
  NCT01885299 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Pennsylvania: Danville, Philadelphia, Pottstown
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Pennsylvania: Philadelphia
• Sacral Neuromodulation for Male Overactive Bladder (MOAB)
  NCT06511141 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Pennsylvania: Bala-Cynwyd
• Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
  NCT06600698 · Phase: Phase 1, Phase 2 · Ages: 40 Years and older · Sex: Male · Pennsylvania: Hershey
• Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
  NCT05283330 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Pittsburgh
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
  NCT03678025 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Chambersburg, Danville, Ephrata, Gettysburg
• Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
  NCT07140900 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia, Pittsburgh
• Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT04221542 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia, Pittsburgh
• Study of AZD0754 in Participants With Metastatic Prostate Cancer
  NCT06267729 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 130 Years · Sex: Male · Pennsylvania: Philadelphia
• Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
  NCT04890613 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Pittsburgh
• Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
  NCT06966024 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia
• Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
  NCT05519449 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: Male · Pennsylvania: Hershey, Philadelphia, Pittsburgh
• Study of ORIC-944 in Patients With Metastatic Prostate Cancer
  NCT05413421 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Bala-Cynwyd, Lancaster
• Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
  NCT06136624 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Pittsburgh
• Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
  NCT07745361 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Lancaster
• Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
  NCT06545942 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
  NCT05176483 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Hershey, Philadelphia, Pittsburgh
• TERPS Trial for de Novo Oligometastic Prostate Cancer
  NCT05223803 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia, Pittsburgh
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
  NCT04485013 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Pittsburgh
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
  NCT06632977 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Sayre
• Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
  NCT05946213 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Beaver, Carlisle, Chadds Ford, Chambersburg
• Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
  NCT06470243 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Allentown, Bethlehem, Chadds Ford, East Stroudsburg
• Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
  NCT06931340 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Erie, Jefferson Hills, Monroeville, Natrona Heights
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
  NCT03866382 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Allentown, Bethlehem, East Stroudsburg, Erie
• The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study
  NCT06064149 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia, Pittsburgh, York
• The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
  NCT04075305 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Pittsburgh
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
  NCT07028853 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Bala-Cynwyd, Lancaster
• Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
  NCT04423211 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Altoona, Beaver, Broomall, Carlisle
• Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
  NCT07493512 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia, Pittsburgh
• Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
  NCT04787744 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: Male · Pennsylvania: Philadelphia
• Virtual Reality Headset and/or Aromatherapy for Patients Undergoing a Transperineal Prostate Biopsy
  NCT06296147 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Pennsylvania: Pittsburgh
• Vitamin D for Prostate Endocrine Therapy
  NCT05838716 · Phase: Phase 3 · Ages: 50 Years and older · Sex: Male · Pennsylvania: Dickson City, Scranton, Wilkes-Barre